Stock AYJ VALNEVA
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Valneva Xetra

Equities

AYJ

FR0004056851

Market Closed - Xetra
Other stock markets
 11:35:47 2024-06-13 am EDT 		After market 01:59:43 pm
3.486 EUR -3.17% Intraday chart for Valneva 3.578 +2.64%
Jun. 04 Pfizer: article on Lyme vaccine in The Lancet CF
Jun. 04 Valneva: article on Lyme vaccine in The Lancet CF

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Valneva : Announces Availability of Documentation for its Shareholder Meeting and Provides Corporate Update
PU
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
GL
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
GL
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GL
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
AQ
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
GL
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
GL
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
GL
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
AQ
Valneva : Q1 2024 Financial Results
PU
Valneva : Reports First Quarter 2024 Financial Results and Provides Corporate Updates
PU
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GL
Valneva : Document AMF CP. 2024E960493
PU
World Vaccine Congress Washington: Antibody persistence of a single-dose live-attenuated chikungunya virus vaccine in adults
PU
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
AQ
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
GL
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
GL
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
AQ
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
AQ
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VLA Stock
  4. AYJ Stock
  5. News Valneva
  6. Press Releases